Global Precision Medicine Market Size, Share, Trends, Growth, and Industry Analysis, By Technology (Bioinformatics, Big Data Analytics, Drug Discovery, Gene Sequencing, Companion Diagnostics, and Others) By Application (CNS, Immunology, Oncology, Respiratory, and Others), By End-use (Diagnostic Companies, Pharmaceutical Companies, Healthcare IT companies, and Others), By Sequencing Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real Time Sequencing, Chain Termination Sequencing and Nanopore Sequencing), By Product (Consumables, Instruments and Services), By Route of Administration (Oral and Injectable), By Drugs (Alectinib, Mepolizumab, Aripiprazole Lauroxil, Osimertinib and Others), Regional Analysis, Competitor Analysis and Forecast 2024-2032.

Global Precision Medicine market size was USD 81.26 billion in 2023 and the market is projected to touch USD 189.02 billion by 2032, at a CAGR of 9.83% during the forecast period. Precision medicine is a cutting-edge approach to medical treatment that takes into account individual features such as genetics, environment, and lifestyle. Precision medicine, as opposed to traditional one-size-fits-all procedures, seeks to improve treatment effectiveness and reduce side effects by examining how each individual's unique circumstances influence their health. This method personalizes care by leveraging modern technology such as genetic testing, molecular diagnostics, and big data analytics.

The global precision medicine market is quickly developing, owing to advances in genetic sequencing technology, a better understanding of disease molecular pathways, and greater desire for individualized healthcare solutions. The market covers a wide range of applications in oncology, neurology, cardiology, and other therapeutic areas. Diagnostic testing for genetic alterations, targeted therapeutics, and companion diagnostics are important components that assist select the most successful treatments for particular patients.

In recent years, pharmaceutical companies, healthcare providers, and research institutions have intensified their efforts in precision medicine, aiming to develop more precise diagnostic tools and innovative therapies. The shift towards value-based healthcare and the growing availability of genomic data are further propelling market growth. Government initiatives and funding support for genomic research and personalized medicine initiatives also play a crucial role in shaping the market landscape.

Global Precision Medicine report scope and segmentation.

Report Attribute

Details

Base Year

2023

Forecast Years

2024 – 2032

Estimated Market Value (2023)

USD   81.26 Billion

Projected Market Value (2032)

USD 189.02 Billion

Segments Covered

By Technology, By Application, By End-Use, By Sequencing Technology, By Product, By Route of Administration, By Drugs, & By Region.

Forecast Units

Value (USD Million or Billion)

Quantitative Units

Revenue in USD million/billion and CAGR from 2024 to 2032.

Regions Covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Countries Covered

U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Australia, Brazil, Argentina, GCC Countries, and South Africa, among others.

Download Free Sample Report

Global Precision Medicine dynamics

Advances in genomic technology, such as next-generation sequencing (NGS), have drastically lowered the cost and duration of genetic testing. This has increased the accessibility of precision medicine approaches, allowing more patients to receive individualized treatments based on their genetic profiles. Furthermore, the growing prevalence of chronic diseases, combined with rising healthcare costs, is driving demand for more effective and efficient therapeutic solutions, which precision medicine promises to provide.

Furthermore, the transition toward value-based healthcare models incentivizes healthcare providers and payers to implement precision medicine tactics, which can possibly enhance patient outcomes and lower overall healthcare costs by eliminating unneeded treatments and adverse medication responses. Moreover, collaborations between pharmaceutical companies, biotechnology firms, and academic institutions are fostering innovation in biomarker discovery, targeted therapy development, and companion diagnostics, driving market growth.

However, challenges such as regulatory complexities, reimbursement issues for genomic testing, and the need for robust data privacy and security measures pose significant hurdles. Nevertheless, ongoing research investments, supportive government policies promoting personalized medicine initiatives, and increasing patient awareness and acceptance are expected to sustain the market's upward trajectory.

Global Precision Medicine drivers

Advancements in Genomic Technologies

Advancements in genomic technology, notably next-generation sequencing (NGS), are a key driver of the precision medicine sector. NGS has accelerated, improved the accuracy, and reduced the cost of genetic sequencing, making it more accessible to healthcare practitioners and patients. This technology allows for a full examination of an individual's genetic makeup, finding precise genetic mutations and variations that influence illness susceptibility and treatment response. As NGS evolves, it promises to broaden the scope of precision medicine beyond oncology to include cardiovascular illnesses, neurology, and uncommon genetic disorders. The ability to conduct large-scale genomic research and integrate genomic data with clinical information improves the development of personalized medicines suited to individual genetic profiles, therefore boosting market growth.

Shift Towards Value-Based Healthcare Models

The global healthcare landscape is transitioning toward value-based care models, which prioritize improving patient outcomes while lowering healthcare expenditures. Precision medicine aligns well with these objectives by providing focused medicines and individualized treatment strategies that maximize efficacy while minimizing side effects. Precision medicine attempts to reduce trial-and-error prescribing while improving treatment outcomes, resulting in long-term cost reductions. Healthcare providers and payers are thus encouraged to use precision medicine approaches that show proven clinical advantages and economic value. This trend is fuelling market expansion as stakeholders see precision medicine's potential to transform healthcare delivery and patient management techniques.

  • Restraints:

Regulatory and Reimbursement Challenges

Regulatory complexity and differing reimbursement rules for genetic diagnostics and tailored medicines represent significant barriers to market growth. Different nations have different legislation regarding genetic testing and data protection, which can impede the general adoption of precision medical technologies. Furthermore, reimbursement policies frequently fall behind technological improvements, generating uncertainty for healthcare professionals and limiting patient access to novel treatments. To address these obstacles, regulatory organizations, healthcare providers, and industry stakeholders must work together to provide clear rules and reimbursement structures that promote precision medicine's inclusion into regular clinical practice.

Data Privacy and Security Concerns

The integration of large-scale genomic and clinical data raises concerns about data privacy and security. Genomic information is highly sensitive and requires robust safeguards to protect patient confidentiality and prevent unauthorized access or misuse. Ensuring compliance with data protection regulations such as GDPR in Europe and HIPAA in the United States is crucial but can be complex and costly for healthcare organizations. Addressing these concerns is essential to building patient trust and facilitating data sharing for research purposes, which is critical for advancing precision medicine initiatives globally.

  • Opportunities:

Expansion into Non-Oncology Applications

While precision medicine first gained popularity in oncology, there is a significant chance to increase its use in other therapeutic areas such as cardiology, neurology, uncommon disorders, and infectious diseases. Advances in biomarker discovery and therapeutic targeting are creating new opportunities for developing individualized treatments that address the underlying causes of many diseases. Collaborations among pharmaceutical corporations, academic institutions, and healthcare providers are pushing research efforts to find biomarkers and create targeted medicines tailored to certain patient populations, thus expanding the market potential beyond cancer.

  • Segment Overview

A variety of innovative technologies propel the precision medicine market forward. Bioinformatics is critical in assessing complicated biological data by combining genomes, proteomics, and clinical information to generate useful insights for individualized treatments. Big data analytics allows for the processing and analysis of massive datasets, facilitating precision medicine by discovering patterns and correlations to help decision-making. Drug discovery technologies focus on developing tailored medicines based on genomic insights, which speeds up the development of personalized treatment choices. Next-generation sequencing (NGS) and nanopore sequencing are two gene sequencing technologies that provide extensive genomic information required for illness diagnosis and treatment prediction. Companion diagnostics assist identify patients likely to benefit from specific medicines and guide treatment decisions based on biological biomarkers.

Precision medicine applications span various therapeutic areas. Central Nervous System (CNS) disorders, including Alzheimer's and Parkinson's diseases, benefit from personalized treatments targeting genetic and environmental factors influencing neurological health. Immunology utilizes precision medicine to tailor therapies for autoimmune diseases and immune system disorders, optimizing treatment efficacy and safety. Oncology remains a primary focus, with precision medicine guiding targeted therapies and predicting cancer progression based on genetic mutations. Respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), also leverage personalized approaches to manage symptoms and improve patient outcomes.

Diagnostic companies play a pivotal role in developing and commercializing genomic tests and biomarker assays essential for precision medicine diagnostics. Pharmaceutical companies integrate genomic insights into drug development pipelines, focusing on personalized therapies that target specific patient populations. Healthcare IT companies provide software solutions for data management, bioinformatics analysis, and clinical decision support, enhancing the integration and utilization of genomic data in healthcare settings.

Global Precision Medicine Overview by Region

North America dominates the market, owing to significant investments in R&D, favourable reimbursement regulations, and broad adoption of advanced genomic technologies. The presence of important actors in the biotechnology and pharmaceutical industries, together with activities by government organizations such as the FDA in the United States, reinforces the region's supremacy. Europe is closely following, with increased collaborations between academic institutions, healthcare providers, and industry players aimed at integrating genomic data into clinical practice. Regulatory authorities such as the European Medicines Agency (EMA) play an important role in licensing and monitoring customized medicine therapies across member states, hence promoting market expansion.

Asia Pacific is positioned for significant development, fuelled by rising healthcare expenditure, expanded access to healthcare services, and greater awareness of individualized treatment alternatives. Countries like China and India are investing in genomic research and infrastructure development to capitalize on precision medicine's potential to address diverse healthcare challenges. However, regulatory complexities and variability in healthcare quality and access remain challenges in some parts of the region. Latin America and the Middle East & Africa regions are also emerging markets, albeit at a slower pace, with increasing initiatives to incorporate precision medicine into healthcare delivery despite infrastructure and economic challenges.

Global Precision Medicine market competitive landscape

Roche, Thermo Fisher Scientific, and Illumina dominate the industry with extensive portfolios of genetic testing platforms, biomarker assays, and companion diagnostics. These corporations use their vast R&D resources and global distribution networks to advance precision medicine technology and broaden market reach.

Furthermore, agreements and partnerships between pharmaceutical giants and biotechnology companies are prevalent, with the goal of co-developing focused medicines and companion diagnostics for specific patient populations. Novartis and Bristol-Myers Squibb are well-known for their efforts in precision oncology and immunotherapy, which incorporate genetic data into medication development and clinical trials.

The market also sees significant participation from diagnostic companies specializing in molecular diagnostics and bioinformatics, providing essential tools and services for genomic data analysis and interpretation. Emerging start-ups and academic spin-offs contribute to the competitive landscape by innovating novel technologies such as single-cell sequencing, liquid biopsy, and AI-driven analytics, which promise to further enhance the precision and efficacy of personalized medicine approaches.

Global Precision Medicine Recent Developments

  • In May 2023, Bayer's Consumer Health Division has inaugurated a specialized business unit dedicated to innovating Precision Health products across its extensive line-up of everyday health categories. This initiative underscores Bayer's commitment to creating solutions that empower individuals to proactively manage their personal health. Central to this effort are digital tools that provide personalized insights, fostering informed decision-making, and innovative delivery methods.
  • In July 2023, Children’s Hospital Colorado has inaugurated the Precision Medicine Institute to enhance diagnostic precision and tailor treatment plans for a range of pediatric conditions. This new initiative utilizes advanced technology to analyse extensive datasets, enabling specialists to develop personalized care strategies for diseases such as cancer, rare neurodegenerative disorders, cystic fibrosis, cardiomyopathy, and more.

Scope of global Precision Medicine report

Global Precision Medicine report segmentation

ATTRIBUTE

DETAILS

By Technology
  • Bioinformatics
  • Big Data Analytics
  • Drug Discovery
  • Gene Sequencing
  • Companion Diagnostics
  • Others

By Application
  • CNS
  • Immunology
  • Oncology
  • Respiratory
  • Others

By End-Use
  • Diagnostic Companies
  • Pharmaceutical Companies
  • Healthcare IT companies
  • Others

By Sequencing Technology
  • Sequencing by Synthesis
  • Ion Semiconductor Sequencing
  • Sequencing by Ligation
  • Pyrosequencing
  • Single Molecule Real Time Sequencing
  • Chain Termination Sequencing
  • Nanopore Sequencing

By Product
  • Consumables
  • Instruments
  • Services

By Route of Administration
  • Oral
  • Injectable

By Drugs
  • Alectinib
  • Osimertinib
  • Mepolizumab
  • Aripiprazole Lauroxil
  • Others

Customization Scope
  • Available upon request

Pricing
  • Available upon request

Table of Contents

  1. 1. Market Scope and Research Methodology
    1. Market Segmentation & Scope
    2. Market Definition
    3. Research Methodology
      1. Our Internal Database
      2. Paid Sources Database
      3. Secondary Sources & Third-Party Perspectives
      4. Primary Research, Experts Interviews and Market Surveys
    4. Research Objective
    5. Data Validation & Publishing
  2. 2. Executive Summary
    1. Market Outlook
    2. Segmental Analysis
  3. 3. Precision Medicine Market Dynamics
    1. Market Introduction
    2. Market Drivers
      1. Advancements in Genomic Technologies  
      2. Shift Towards Value-Based Healthcare Models  
    3. Market Restraints
      1. Regulatory and Reimbursement Challenges  
      2. Data Privacy and Security Concerns  
    4. Industry Challenges
    5. Industry Opportunities
    6. Regulatory Frameworks
    7. Patent Trends
    8. Covid-19 Impact Analysis
    9. Market Strategic Analysis
      1. Industry Analysis – Porter’s
        1. Supplier Power
        2. Buyer Power
        3. Substitution Threat
        4. Threat from New Entrant
        5. Competitive Rivalry
      2. PESTEL Analysis
      3. Consumer behaviour analysis
        1. Consumer response to the product
        2. Factors affecting buying decision
        3. Other recommendations
  4. 4. Precision Medicine Market: Technology Estimates & Trend Analysis
    1. Technology Movement Analysis & Market Share, 2023 & 2032
    2. Bioinformatics
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    3. Big Data Analytics
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    4. Drug Discovery
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    5. Gene Sequencing
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    6. Companion Diagnostics
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    7. Others
      1. Market estimates and forecast, 2024-2032, (USD Billion)
  5. 5. Precision Medicine Market: Application Estimates & Trend Analysis
    1. Application Movement Analysis & Market Share, 2023 & 2032
    2. CNS
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    3. Immunology
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    4. Oncology
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    5. Respiratory
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    6. Others
      1. Market estimates and forecast, 2024-2032, (USD Billion)
  6. 6. Precision Medicine Market: End-Use Estimates & Trend Analysis
    1. End-Use Movement Analysis & Market Share, 2023 & 2032
    2. Diagnostic Companies
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    3. Pharmaceutical Companies
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    4. Healthcare IT companies
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    5. Others
      1. Market estimates and forecast, 2024-2032, (USD Billion)
  7. 7. Precision Medicine Market: Sequencing Technology Estimates & Trend Analysis
    1. Sequencing Technology Movement Analysis & Market Share, 2023 & 2032
    2. Sequencing by Synthesis  
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    3. Ion Semiconductor Sequencing
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    4. Sequencing by Ligation
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    5. Pyrosequencing
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    6. Single Molecule Real Time Sequencing
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    7. Chain Termination Sequencing
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    8. Nanopore Sequencing
      1. Market estimates and forecast, 2024-2032, (USD Billion)
  8. 8. Precision Medicine Market: Product Estimates & Trend Analysis
    1. Product Movement Analysis & Market Share, 2023 & 2032
    2. Consumables
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    3. Instruments
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    4. Services
      1. Market estimates and forecast, 2024-2032, (USD Billion)
  9. 9. Precision Medicine Market: Route of Administration Estimates & Trend Analysis
    1. Route of Administration Movement Analysis & Market Share, 2023 & 2032
    2. Oral
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    3. Injectable
      1. Market estimates and forecast, 2024-2032, (USD Billion)
  10. 10. Precision Medicine Market: Drugs Estimates & Trend Analysis
    1. Drugs Movement Analysis & Market Share, 2023 & 2032
    2. Alectinib
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    3. Osimertinib
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    4. Mepolizumab
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    5. Aripiprazole Lauroxil
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    6. Others
      1. Market estimates and forecast, 2024-2032, (USD Billion)
  11. 11. Precision Medicine Market: Regional Estimates & Trend Analysis
    1. Regional Movement Analysis & Market Share, 2023 & 2032
    2. North America
      1. Market estimates and forecast, 2024-2032, (USD Billion)
      2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
      3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
      4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
      5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
      6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
      7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
      8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      9. U.S.
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      10. Canada
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
    3. Europe
      1. Market estimates and forecast, 2024-2032, (USD Billion)
      2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
      3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
      4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
      5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
      6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
      7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
      8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      9. Germany
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      10. UK
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      11. France
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      12. Spain
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      13. Rest of Europe
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
    4. Asia Pacific
      1. Market estimates and forecast, 2024-2032, (USD Billion)
      2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
      3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
      4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
      5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
      6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
      7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
      8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      9. China
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      10. India
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      11. Japan
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      12. South Korea
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      13. Australia
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      14. Southeast Asia
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      15. Rest of Asia Pacific
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
    5. Middle East & Africa
      1. Market estimates and forecast, 2024-2032, (USD Billion)
      2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
      3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
      4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
      5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
      6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
      7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
      8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      9. GCC
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      10. Turkey
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      11. Africa
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      12. Rest of MEA
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
    6. Latin America
      1. Market estimates and forecast, 2024-2032, (USD Billion)
      2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
      3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
      4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
      5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
      6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
      7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
      8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      9. Brazil
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      10. Mexico
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      11. Argentina
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
      12. Rest of Latin America
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Technology, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by End-Use, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Sequencing Technology, 2024-2032, (USD Billion)
        6. Market estimates and forecast, by Product, 2024-2032, (USD Billion)
        7. Market estimates and forecast, by Route of Administration, 2024-2032, (USD Billion)
        8. Market estimates and forecast, by Drugs, 2024-2032, (USD Billion)
  12. 12. Competitive Analysis
    1. Key global players, recent developments & their impact on the industry
    2. Key Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
    3. Vendor Landscape
      1. Key company market share analysis, 2021
  13. 13. Company Profiles
    1. Novartis
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    2. Roche
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    3. Pfizer
      1.  Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    4. Teva Pharmaceutical  
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    5. Qiagen
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    6. Quest Diagnostics
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    7. Menarini Silicon Biosystems
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    8. NanoString Technologies
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    9. Eagle Genomics
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    10. Biocrates Life Sciences
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    11. Tepnel Pharma Services
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    12. Intomics
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis  


In case you don’t find what, you are looking for, please get in touch with our custom research team at sales@organicmarketresearch.com or Download Free Sample Report

  • What is the study period of global Precision Medicine report?
    Global Precision Medicine forecast period is 2024 - 2032
  • What is the expected global Precision Medicine growth rate during the forecast period?
    According to global Precision Medicine research, the market is expected to grow at a CAGR of ~ 9.83% over the next eight years.
  • What is the expected market size for Global Precision Medicine?
    The expected market size for Global Precision Medicine is USD 189.02 billion in 2032.
  • What are the possible segments in global Precision Medicine?
    The possible segments in global Precision Medicine are based on By Technology, By Application, By End-Use, By Sequencing Technology, By Product, By Route of Administration, By Drugs, & by region.
  • Who are the key players in Global Precision Medicine?
    The major players in the market are Novartis, Roche, Pfizer, Teva Pharmaceutical, Qiagen, Quest Diagnostics, Menarini Silicon Biosystems, NanoString Technologies, Eagle Genomics, Biocrates Life Sciences, Tepnel Pharma Services, and Intomics.
  • Buy Now

Speak To Consultant

or Face to Face Meeting

Why Choose Us

  • 24x7 Post-Sales Support
  • 4000+ Reports Repository
  • 10% Free Customization
  • Large Network Of Industry Experts
  • Deep Sector Specific Intelligence
  • Unique Mix Of Global, Regional And Country Specific Reports

Related Reports

Recent News

Why Buy From Us?

Succeed

Our reports with in-depth insights will equip you to succeed in your business plans.

Instant Access

Get instant access to the information you need to make the right decision.

Opportunities

Explore where opportunities lie for you and mitigate the risks.

Trusted

We are one of the most trusted brands setting benchmarks of excellence.